IN2015MN00002A - - Google Patents
Info
- Publication number
- IN2015MN00002A IN2015MN00002A IN2MUN2015A IN2015MN00002A IN 2015MN00002 A IN2015MN00002 A IN 2015MN00002A IN 2MUN2015 A IN2MUN2015 A IN 2MUN2015A IN 2015MN00002 A IN2015MN00002 A IN 2015MN00002A
- Authority
- IN
- India
- Prior art keywords
- stereoisomer
- amenable
- disorders
- inhibiting
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2MUN2015 IN2015MN00002A (zh) | 2012-07-09 | 2013-07-09 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN762KO2012 | 2012-07-09 | ||
| PCT/IB2013/055618 WO2014009872A1 (en) | 2012-07-09 | 2013-07-09 | Tetrahydroquinazolinone derivatives as parp inhibitors |
| IN2MUN2015 IN2015MN00002A (zh) | 2012-07-09 | 2013-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015MN00002A true IN2015MN00002A (zh) | 2015-10-16 |
Family
ID=48906465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2MUN2015 IN2015MN00002A (zh) | 2012-07-09 | 2013-07-09 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9359367B2 (zh) |
| EP (1) | EP2870140B8 (zh) |
| AU (1) | AU2013288265B2 (zh) |
| CA (1) | CA2877826C (zh) |
| ES (1) | ES2595240T3 (zh) |
| IN (1) | IN2015MN00002A (zh) |
| WO (1) | WO2014009872A1 (zh) |
| ZA (1) | ZA201409497B (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2672722C2 (ru) | 2014-04-10 | 2018-11-19 | Хубэй Био-Фармасьютикал Индастриал Текнолоджикал Инститьют Инк. | Аналоги соединений 4н-пиразоло[1,5-а]бензимидазола в качестве ингибиторов parp |
| WO2016012956A1 (en) * | 2014-07-24 | 2016-01-28 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
| WO2017013593A1 (en) | 2015-07-22 | 2017-01-26 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
| CA2991232A1 (en) * | 2015-08-17 | 2017-02-23 | Lupin Limited | Heteroaryl derivatives as parp inhibitors |
| CN108822115B (zh) * | 2017-04-21 | 2022-08-12 | 上海迪诺医药科技有限公司 | 一种抑制parp活性的化合物的制备方法及其中间体 |
| TWI813611B (zh) | 2017-12-21 | 2023-09-01 | 美商律幫治療股份有限公司 | 作為parp14抑制劑之喹唑啉酮 |
| CN111269216A (zh) * | 2018-12-05 | 2020-06-12 | 中国医学科学院药物研究所 | 含有哌嗪酮的喹唑啉二酮盐类化合物、其制备方法、药物组合物和用途 |
| TWI749881B (zh) * | 2019-11-21 | 2021-12-11 | 大陸商深圳信立泰藥業股份有限公司 | 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 |
| CN112608303B (zh) * | 2020-12-25 | 2021-10-26 | 华南理工大学 | 一种哌嗪类中间体及其制备方法与应用 |
| CN114044769B (zh) * | 2021-11-25 | 2023-12-12 | 中山大学 | 一种β-吲哚喹唑啉酮衍生物及其制备方法和应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2027645A1 (de) | 1970-06-05 | 1971-12-09 | Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz | Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel |
| BE503170A (zh) | 1975-09-02 | |||
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| IL90858A (en) | 1988-07-07 | 1994-08-26 | Rhone Poulenc Sante | History (Aza) Naftalensultam, their preparation and preparations containing them |
| DE4312832C1 (de) | 1993-04-20 | 1994-10-20 | Boehringer Ingelheim Kg | Verfahren zur Herstellung enantiomerenreiner Ketale der (S)- und (R)-3-Oxocyclopentancarbonsäure |
| DE4316576A1 (de) | 1993-05-18 | 1994-11-24 | Boehringer Ingelheim Kg | Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin |
| US5589489A (en) | 1993-12-15 | 1996-12-31 | Zeneca Limited | Cyclic amide derivatives for treating asthma |
| GB9904275D0 (en) | 1999-02-24 | 1999-04-21 | Cancer Res Campaign Tech | Anti-cancer compounds |
| US20020082268A1 (en) | 2000-03-20 | 2002-06-27 | Yun Gao | Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof |
| EP1178047B1 (en) | 2000-08-03 | 2004-02-25 | Pfizer Products Inc. | Diazabicyclooctane derivatives and therapeutic uses thereof |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| WO2002094790A1 (fr) * | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Compose heterocyclique condense et son utilisation medicale |
| OA12698A (en) | 2001-07-11 | 2006-06-22 | Elan Pharm Inc | N-(3-amino-2-hydroxy-propyl)substituted alkylamidecompounds. |
| AUPR975601A0 (en) | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
| AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| JP2005536553A (ja) | 2002-08-21 | 2005-12-02 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| CN1266155C (zh) | 2003-08-01 | 2006-07-26 | 浙江震元制药有限公司 | 6－氯－4－羟基－2－甲基－2H－噻吩并（2，3－e）－1，2－噻嗪－1，1－二氧化物－3－羧酸酯的合成方法 |
| US7767683B2 (en) | 2003-08-18 | 2010-08-03 | H. Lundbeck A/S | Hydrogen succinate salts of trans-4-((1R, 3S)-6-chloro-3-phenylindan-1-YL)-1,2,2-trimethylpiperazine and the use as a medicament |
| US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| TWI338000B (en) | 2003-12-01 | 2011-03-01 | Kudos Pharm Ltd | Dna damage repair inhibitors for treatment of cancer |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| AU2005217320B2 (en) | 2004-02-26 | 2011-07-21 | Aska Pharmaceuticals Co., Ltd. | Pyrimidine derivative |
| US7381822B2 (en) | 2004-03-31 | 2008-06-03 | The General Hospital Corporation | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process |
| US20050245534A1 (en) | 2004-04-29 | 2005-11-03 | Link James T | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| EP1740551B9 (en) | 2004-04-30 | 2013-01-16 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof as an mmp-13 inhibitor |
| UA86237C2 (uk) | 2004-06-30 | 2009-04-10 | Янссен Фармацевтика Н.В. | Похідні заміщеного 2-алкілхіназолінону як інгібітори parp |
| US20060079510A1 (en) | 2004-09-30 | 2006-04-13 | Kristoffer Hellstrand | Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis |
| WO2006051851A1 (ja) | 2004-11-10 | 2006-05-18 | Wakamoto Pharmaceutical Co., Ltd. | ２，３，４，５－テトラヒドロ－１ｈ－１，５－ベンゾジアゼピン誘導体、及び、医薬組成物 |
| EP1828183A1 (en) | 2004-12-17 | 2007-09-05 | AstraZeneca AB | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
| SI1863787T1 (sl) | 2005-03-23 | 2011-10-28 | Actelion Pharmaceuticals Ltd | Hidrogenirani benzo(c)tiofenski derivati kot imunomodulatorji |
| US20090226412A1 (en) | 2005-06-24 | 2009-09-10 | Ono Pharmaceutical Co., Ltd., | Agent for reduction of bleeding in cerebrovascular disorder |
| US7300947B2 (en) | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| CN101263125A (zh) | 2005-07-15 | 2008-09-10 | 先灵公司 | 用于癌症治疗的喹唑啉衍生物 |
| ATE499098T1 (de) | 2005-11-25 | 2011-03-15 | Pharma Mar Sa | Verwendung von parp-1-hemmern |
| EP1968968A1 (en) | 2005-12-21 | 2008-09-17 | PainCeptor Pharma Corp. | Compositions and methods for modulating gated ion channels |
| WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| EP2233472B1 (en) | 2006-03-28 | 2014-01-15 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| AU2007243457B2 (en) | 2006-04-26 | 2012-02-23 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
| WO2008080824A1 (en) | 2006-12-29 | 2008-07-10 | F. Hoffmann-La Roche Ag | Aromatic sulfonated ketals |
| EP2208728A4 (en) | 2007-09-19 | 2011-12-21 | Inst Med Molecular Design Inc | HETEROCYCLIC DERIVATIVE DERIVATIVE DERIVATIVE TO 11 -? - HYDROXYSTEROIDDEHYDROGENASE TYPE I |
| WO2009041565A1 (ja) | 2007-09-26 | 2009-04-02 | Santen Pharmaceutical Co., Ltd. | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤 |
| JP2009196973A (ja) | 2007-09-26 | 2009-09-03 | Santen Pharmaceut Co Ltd | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤 |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| FR2926221A1 (fr) | 2008-01-14 | 2009-07-17 | Tassin Thomas | Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand. |
| WO2009114459A2 (en) | 2008-03-10 | 2009-09-17 | The Trustees Of The University Of Pennsylvania | Anti-neoplastic combination therapeutic regimen involving co-disruption of parp pathway and mre11/rad50/nbs1 complex and compositons useful therein |
| MX2011005597A (es) | 2008-12-05 | 2011-06-16 | Hoffmann La Roche | Pirrolopirazinil-ureas como inhibidores de cinasas. |
| WO2010082813A1 (en) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Method of treating cancer |
| KR20130040834A (ko) | 2010-03-25 | 2013-04-24 | 아비에 인코포레이티드 | 암 및 면역 및 자가면역 질환의 치료를 위한 아폽토시스―유도제 |
| RU2013114710A (ru) | 2010-09-03 | 2014-10-10 | Байер Интеллектуэль Проперти Гмбх | Замещенные конденсированные пиримидиноны и дигидропиримидиноны |
-
2013
- 2013-07-09 WO PCT/IB2013/055618 patent/WO2014009872A1/en active Application Filing
- 2013-07-09 IN IN2MUN2015 patent/IN2015MN00002A/en unknown
- 2013-07-09 US US14/411,968 patent/US9359367B2/en not_active Expired - Fee Related
- 2013-07-09 ES ES13742752.2T patent/ES2595240T3/es active Active
- 2013-07-09 AU AU2013288265A patent/AU2013288265B2/en not_active Ceased
- 2013-07-09 CA CA2877826A patent/CA2877826C/en not_active Expired - Fee Related
- 2013-07-09 EP EP13742752.2A patent/EP2870140B8/en not_active Not-in-force
-
2014
- 2014-12-23 ZA ZA2014/09497A patent/ZA201409497B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9359367B2 (en) | 2016-06-07 |
| AU2013288265A1 (en) | 2015-01-29 |
| AU2013288265B2 (en) | 2017-04-06 |
| EP2870140B1 (en) | 2016-07-27 |
| CA2877826A1 (en) | 2014-01-16 |
| EP2870140A1 (en) | 2015-05-13 |
| ES2595240T3 (es) | 2016-12-28 |
| ZA201409497B (en) | 2015-12-23 |
| EP2870140B8 (en) | 2016-09-28 |
| WO2014009872A1 (en) | 2014-01-16 |
| US20150152118A1 (en) | 2015-06-04 |
| CA2877826C (en) | 2016-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500360A1 (en) | Heteroaryl derivatives as parp inhibitors | |
| IN2015MN00002A (zh) | ||
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
| PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| MX2023001876A (es) | Derivados de rapamicina. | |
| MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| MX2015011245A (es) | Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer. | |
| PH12017500007A1 (en) | Quinolizinone derivatives as p13k inhibitors | |
| MD4659B1 (ro) | Polimorf al inhibitorilor SYK | |
| MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
| MX2014014106A (es) | Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral. | |
| NZ705253A (en) | Derivatives of azaindazole or diazaindazole type for treating pain | |
| MX2013011591A (es) | Métodos y composiciones para tratar enfermedades neurodegenerativas. | |
| MY184858A (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
| WO2014155300A3 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| CA2881554C (en) | Methods for inhibiting fascin | |
| MX2014003801A (es) | Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| NZ706591A (en) | Oxazolidin-2-one-pyrimidine derivatives | |
| MX362896B (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| MX2015008288A (es) | Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| MX2016004967A (es) | Tratamiento para cancer pancreatico. |